| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Angiogenin is a key mediator of angiogenesis, and its 108-122 fragment may interact with binding sites or cellular targets involved in angiogenin's ribonucleolytic activity and pro-angiogenic signaling pathways.
|
|---|---|
| ln Vitro |
Angiogenin(108-122) has a 39% inhibition on its ribonucleolytic activity when employing tRNA as the substrate[1]. A number of diseases, including cancer, infectious diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, autoimmune diseases, and cardiac and vascular diseases, can be prevented or treated by angiogenin (108–122).
In enzymatic assays using tRNA as a substrate, Angiogenin (108-122) shows approximately 39% inhibition of ribonucleolytic activity, indicating its ability to modulate angiogenin's enzymatic function. It may interfere with the protein's active site or substrate binding. |
| ln Vivo |
The peptide has been investigated as a potential therapeutic agent for a range of diseases, including cancer, infectious diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, autoimmune diseases, and cardiovascular disorders.
|
| Enzyme Assay |
Non-cellular assays involve incubating recombinant angiogenin with tRNA in the presence of varying concentrations of the peptide fragment, followed by measuring ribonucleolytic activity via acid precipitation and absorbance detection at 260 nm to quantify RNA cleavage.
|
| Cell Assay |
In cell culture studies, the peptide is added to endothelial cells or cancer cell lines at various concentrations (typically 1-100 uM). Endpoints include cell proliferation (MTT assay), migration (scratch assay), and tube formation (Matrigel assay) to assess anti-angiogenic effects.
|
| Animal Protocol |
In preclinical animal models of disease (e.g., tumor xenografts, fibrosis models, or inflammatory disease models), the peptide is administered via intravenous or intraperitoneal injection at doses ranging from 1-20 mg/kg. Disease progression, survival, and histopathological parameters are monitored.
|
| ADME/Pharmacokinetics |
As a peptide, Angiogenin (108-122) is expected to have a relatively short half-life in circulation due to rapid proteolytic degradation. Its bioavailability is limited, and it requires frequent dosing or formulation in sustained-release systems for in vivo efficacy.
|
| Toxicity/Toxicokinetics |
In preclinical studies, no severe toxicity or adverse effects have been reported at therapeutic doses. Standard safety assessments (e.g., body weight, organ histopathology, serum biochemistry) show an acceptable safety profile.
|
| References | |
| Additional Infomation |
This peptide is a fragment of the human angiogenin protein, a member of the RNase A superfamily. It is not FDA-approved for clinical use but has shown promise in preclinical models. Strictly a research-grade peptide for investigational use only.
|
| Molecular Formula |
C80H126F3N25O25
|
|---|---|
| Molecular Weight |
1895.00
|
| Related CAS # |
Angiogenin (108-122);112173-49-6
|
| Appearance |
Typically exists as solid at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O :≥ 50 mg/mL (~26.39 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 25 mg/mL (13.19 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.5277 mL | 2.6385 mL | 5.2770 mL | |
| 5 mM | 0.1055 mL | 0.5277 mL | 1.0554 mL | |
| 10 mM | 0.0528 mL | 0.2639 mL | 0.5277 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
